Adults with type 2 diabetes who used a continuous glucose monitor spent about five more hours each day with their blood sugar in a healthy target range, according to the largest clinical trial of its kind, published in the New England Journal of Medicine and reported by the University of Colorado Anschutz Medical Campus. The finding matters because most research on continuous glucose monitors, or CGMs, has focused on people with type 1 diabetes or on people with type 2 diabetes who use insulin. This trial extends the evidence to a much larger group: adults managing type 2 diabetes without insulin.
Instead of relying only on occasional finger-stick checks or a quarterly A1C test, CGM users wear a small sensor, usually on the arm or abdomen, that measures glucose in the fluid under the skin every few minutes. The readings are sent to a phone or receiver, showing not just a single number but a direction — rising, falling or steady — and a full picture of what happens overnight, after meals and during exercise. For many participants, that visibility appears to have changed daily decisions in small, cumulative ways that added up to hours more time in range.
What the Trial Found
Researchers described the study as the largest trial of its kind in this population, and the headline result was consistent: people randomised to use a CGM spent roughly five additional hours per day in target range compared with those receiving usual care without a monitor. Coverage of the trial shared on Reddit’s r/science community drew wide attention, while the University of Colorado Anschutz report summarised the same conclusion in plain terms: more time in a healthy range, every day.
Time in range is increasingly treated by diabetes specialists as a useful measure alongside A1C. A1C shows an average over about three months, but it cannot show how often glucose swings too high after breakfast or dips too low at night. Time in range captures those patterns. Spending more hours in range is associated in the wider literature with a lower risk of long-term complications affecting the eyes, kidneys, nerves and cardiovascular system, although longer follow-up is needed to show how the gains in this trial translate into outcomes over years.
Why It Matters for People Not Using Insulin
Type 2 diabetes is often managed first with lifestyle changes and oral or non-insulin medicines. Because those treatments carry a lower risk of severe low blood sugar than insulin, monitors have historically been prescribed less often — and reimbursed less often — for this group. That created a gap: the people least likely to be offered a CGM were also the people with the least information about how food, activity, sleep and stress affect their own glucose.
The trial challenges that logic. Participants could see, in near real time, that a walk after dinner blunted a glucose rise, that a particular breakfast caused a sharp spike, or that poor sleep was followed by higher readings the next morning. Clinicians involved in this field often describe that feedback loop as the real intervention. The sensor itself does not lower glucose; the decisions made with its data do. Without a monitor, those same decisions are largely guesswork.
Access, Cost and the Questions That Remain
The results are likely to intensify debate about who should be offered a CGM and who pays for it. Sensors must be replaced regularly, and costs add up even when the per-day price has fallen. Insurers and health systems will ask whether five more hours in range, sustained over time, reduces expensive complications enough to justify wider coverage. Patient groups argue that the quality-of-life case is already strong: fewer finger sticks, fewer surprises and a clearer sense of control.
There are also practical limits. CGMs require a compatible phone or receiver, basic digital confidence and skin that tolerates adhesive sensors. Readings can lag behind blood glucose during rapid changes, and alarms — where available — can cause anxiety or alert fatigue for some users. Trial participants also receive support and follow-up that may not match routine care, so real-world results could be smaller. Even so, the direction of the evidence is difficult to ignore.
For readers following other health and technology coverage on this site, our recent posts explore how digital tools are reshaping everyday life, from what goes into building a smooth browser game to maintaining a balanced approach to gaming communities — a reminder that good feedback, in health as in technology, helps people adjust before small problems become big ones.
The Bottom Line
This trial does not suggest that everyone with type 2 diabetes must wear a sensor tomorrow, and it does not replace medical advice, medication or regular A1C testing. What it does show, at unusual scale, is that continuous information helps people who are not using insulin keep their glucose in a healthy range for a substantially larger share of the day. If access expands to match the evidence, the humble arm sensor could become a standard part of type 2 care rather than an exception reserved for a minority of patients.